MATN Insider Trading Activity and SEC Form 4 Filings
MATN insider trading summary
No open-market insider purchases or sales of Mateon Therapeutics Inc (MATN) have been reported on SEC Form 4 in the past 12 months.
Latest MATN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 24, 2020 | Amit B. Shah | Chief Financial Officer | Buy | $2K (8,220 @ $0.19) |
| Nov 23, 2020 | Amit B. Shah | Chief Financial Officer | Buy | $4K (20,088 @ $0.19) |
| Nov 20, 2020 | Amit B. Shah | Chief Financial Officer | Buy | $6K (31,692 @ $0.20) |
| Nov 19, 2020 | Vuong Trieu | Chief Executive Officer | Buy | $10K (50,500 @ $0.19) |
| Nov 19, 2020 | Chulho Park | Chief Technology Officer | Buy | $4K (22,173 @ $0.18) |
| Mar 26, 2020 | Vuong Trieu | Chief Executive Officer | Buy | $360 (3,000 @ $0.12) |
| Apr 12, 2018 | Matthew M Loar | Chief Financial Officer | Buy | $0 (250,000 @ $0.00) |
| Apr 12, 2018 | William D Schwieterman | President and CEO | Buy | $0 (625,000 @ $0.00) |
| Apr 12, 2018 | Donald Rogers Reynolds | Director | Buy | $0 (250,000 @ $0.00) |
| Dec 16, 2016 | Donald Rogers Reynolds | Director | Buy | $4K (12,700 @ $0.34) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.